Table 3.
Estimated percent reduction (%) for overall and estrogen receptor–specific breast cancer mortality rates in 2000 attributable to adjuvant treatment and/or screening, relative to no screening and no adjuvant treatment, for women aged 30 to 79 years*
| Model | All breast cancer cases | ER+ breast cancer cases | ER- breast cancer cases | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tam | Chemo | TX | SCR | SCR+TX | Tam | Chemo | TX | SCR | SCR+TX | Tam | Chemo | TX | SCR | SCR+TX | |
| D | 9.7 | 8.0 | 17.3 | 14.8 | 30.2 | 13.8 | 5.5 | 18.8 | 16.0 | 32.7 | 0 | 13.8 | 13.8 | 11.6 | 23.6 |
| E | 13.6 | 12.1 | 24.7 | 14.5 | 35.0 | 19.7 | 9.0 | 27.2 | 15.2 | 37.5 | 0 | 19.1 | 19.1 | 13.0 | 29.2 |
| G-E | 11.1 | 7.9 | 18.5 | 20.0 | 34.6 | 16.1 | 5.7 | 20.5 | 20.8 | 37.0 | 0 | 13.9 | 13.9 | 18.1 | 29.1 |
| M | 14.3 | 7.6 | 22.2 | 15.3 | 28.2 | 19.1 | 4.7 | 24.2 | 15.8 | 31.5 | 0 | 16.4 | 16.4 | 14.0 | 18.6 |
| S | 18.3 | 8.9 | 25.3 | 21.4 | 38.8 | 24.7 | 7.5 | 30.1 | 22.5 | 43.4 | 0 | 13.1 | 13.1 | 14.1 | 25.3 |
| W | 16.4 | 10.5 | 26.3 | 16.4 | 39.4 | 23.4 | 6.8 | 29.4 | 17.4 | 42.9 | 0 | 19.1 | 19.1 | 14.2 | 31.2 |
| Median | 13.9 | 8.5 | 23.4 | 15.9 | 34.8 | 19.4 | 6.3 | 25.7 | 16.7 | 37.3 | 0 | 15.1 | 15.1 | 14.0 | 27.2 |
* Percentages are computed as the difference between the rate predicted in the absence of screening and treatment and the rate predicted with one or both interventions, divided by the rate predicted in the absence of screening and treatment. Chemo = chemotherapy; ER = estrogen receptor; SCR = screening mammography; SCR+TX = screening mammography and tamoxifen and chemotherapy; Tam = tamoxifen; TX = tamoxifen and chemotherapy.